The Fly

Medavail price target lowered to $1 from $4 at Lake Street

Lake Street analyst Brooks O’Neil lowered the firm’s price target on Medavail (MDVL) to $1 from $4 and keeps a Buy rating on the shares after the company announced last week the execution of a strategic restructuring and reprioritization of its business targeted to deliver profitability and announced this morning an agreement to sell certain assets of MedAvail’s SpotRx pharmacies to CVS Pharmacy (CVS). The firm "admittedly, is looking down the road" with its price target, it tells investors, "but this transaction is buying us some time, and we plan to stick around and see what management can make of it," Lake Street added.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on MDVL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More